Name

Biomaster

Legal name

株式会社バイオマスター (Biomaster, Inc.)

Website

https://biomaster.jp

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)

Keywords

• Regenerative medicine services
• Cell processing services
• Adipose stem cell therapy
• Cell concentration systems
• Breast reconstruction treatment

Headquarters

HQ city

Yokohama-shi

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Cell Processing Contract Business (细胞加工受托事业): Medical institutions send collected adipose tissue, Biomaster separates and cultures adipose-derived stem cells at its registered Cell Processing Facility (CPC) and returns them. Revenue is generated through cell processing fees charged to medical institutions. The CPC is registered with the Ministry of Health, Labour and Welfare under the Act on the Safety of Regenerative Medicine.
2. Cell Concentration Washing System Sales: Sale of the Kaneka-developed cell concentration washing system and disposable kits to medical institutions. Institutions use the system for in-house SVF separation and extraction.
3. Clinic Services (Cellport Clinic Yokohama): Direct patient services through the company's own clinic, providing CAL and cultured CAL breast reconstruction and related treatments. Operated under the Structural Reform Special Zones Act.
4. Application and Technical Support Services: Support services for medical institutions seeking to offer regenerative medicine, including preparation of application documents for the Regenerative Medicine Safety Act, technical guidance, and physician/technician dispatch as needed.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Biomaster is a regenerative medicine research and development company that provides cell processing contract services, cell concentration washing systems, and regulatory/technical support to medical institutions in Japan. It also operates Cellport Clinic Yokohama, where it delivers proprietary CAL (Cell Assisted Lipotransfer), Cultured CAL, and Step-CAL breast reconstruction and regenerative treatments directly to patients using adipose-derived stem cells.

Product overview

Biomaster is a research and development company specializing in regenerative medicine, offering a portfolio of three integrated regenerative medicine solutions: (1) Cell Processing Contract Business for third-party medical institutions, (2) Cell Concentration Washing System (KaneKa) equipment sales, and (3) Application/Technical Support for regenerative medicine approvals. Additionally, Biomaster operates Cellport Clinic Yokohama, which directly provides CAL (Cell Assisted Lipotransfer) and Cultured CAL treatments to patients, including the branded stem cell product PortStem.

Differentiator

Problem solved

Functional benefit

Brands

• CAL組織増大術 (CAL): Cell Assisted Lipotransfer - regenerative medicine technique combining patient fat with adipose-derived stem cells to improve fat graft survival rates
• PortStem
• セルポートクリニック横浜 (Cellport Clinic Yokohama)

Products and services

• CAL (Cell Assisted Lipotransfer) Tissue Augmentation Regenerative medicine treatment in which the patient's own fat is combined with adipose-derived stem cells before injection, improving the survival rate of injected fat. Co-developed by Biomaster and the University of Tokyo Faculty of Medicine; provided at Cellport Clinic Yokohama.
• Cultured CAL Regenerative medicine treatment that adds cultured adipose-derived stem cells to the patient's fat for injection, for breast reconstruction and related applications. Clinical trials conducted from 2015 with treatment provided since 2020.
• PortStem (cultured adipose-derived stem cell product) Trademarked brand of cultivated adipose-derived stem cells developed by Biomaster, first clinically used at Cellport Clinic Yokohama.
• Cell Processing Contract Business Third-party cell processing service for medical institutions: clients send collected adipose tissue, and Biomaster isolates, cultures, and proliferates adipose-derived stem cells at its registered CPC using Kaneka-developed high-proliferation culture methods, then returns the cells.
• Cell Concentration Washing System Automated closed-circuit system that concentrates and washes cell suspensions and, with dedicated accessories, separates and extracts adipose-derived stem cells from adipose tissue; processes 50mL of adipose tissue to isolate SVF within 100 minutes. Developed and manufactured by Kaneka.
• Application Document Creation Support Support service for medical institutions preparing to offer regenerative medicine, including application document preparation under the Act on the Safety of Regenerative Medicine, periodic report preparation, technical support, and physician/technician dispatch.
• Cellport Clinic Yokohama Clinic operated by Biomaster in Yokohama under the Structural Reform Special Zones Act, providing CAL and Cultured CAL breast reconstruction and related regenerative treatments directly to patients.

Quantifiable outcome

• 1,300+ CAL procedures performed (as of June 2021)
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• 株式会社カネカ (Kaneka Corporation)coreTechnology or Integration · 1 January 2011Since 2011, Biomaster has been part of the Kaneka Group. Kaneka provides high-proliferation culture methods for stem cell cultivation and manufactures the cell concentration washing system. Biomaster uses Kaneka's technology and equipment for its cell processing services and resells Kaneka's products to medical institutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nikon CeLL innovation Co., Ltd. Subsidiary of Nikon providing cell processing and contract manufacturing services for regenerative medicine in Japan. Directly comparable to Biomaster as a domestic Japanese cell processing CDMO serving medical institutions under the regenerative medicine safety framework.
• MEDINET Co., Ltd. Japanese cell therapy and regenerative medicine company providing cell processing services to medical institutions. Highly comparable to Biomaster's B2B cell processing contract model and use of approved regenerative medicine plans under Japan's Act on the Safety of Regenerative Medicine.
• Resonac Corporation (formerly Hitachi Chemical): Japan-based CDMO with a dedicated regenerative medicine business providing cell processing, contract manufacturing, and CPC services to Japanese medical institutions. Closely comparable in service offering, regulatory positioning, and customer segment to Biomaster.
• CellGenix GmbH: Cell and gene therapy-focused CDMO supplying GMP-grade cell culture reagents, cytokines, and contract manufacturing services. Directly comparable to Biomaster's cell processing contract services and CPC-based biologics manufacturing for regenerative medicine.

Regional players

• Beike Biotechnology: China-based regenerative medicine company focused on umbilical cord mesenchymal stem cell therapies. Comparable as a stem cell therapy company with clinical application focus, and historical investor/affiliate in Biomaster's funding history.
• JCR Pharmaceuticals Co., Ltd. Japan-based biopharmaceutical company with established cell therapy and regenerative medicine franchises, including TEMCELL for GvHD. Comparable as a domestic Japanese developer of cell-based therapies with strong regulatory navigation and clinical experience.

Broad incumbents

• Catalent, Inc. Major global CDMO with cell therapy and biologics manufacturing capabilities. Comparable as a contract developer/manufacturer serving regenerative medicine customers, albeit at a much larger scale and broader geographic scope than Biomaster.
• Lonza Group AG: Global biopharmaceutical CDMO with one of the largest cell and gene therapy manufacturing footprints. Comparable as a biologics/cell therapy CDMO, though much larger and more international than Biomaster's domestic-focused model.

Others

• Cytiva (Danaher): Global supplier of bioprocessing equipment, single-use systems, and cell therapy manufacturing solutions. Comparable to Biomaster's Kaneka cell concentration washing system distribution and the broader bioprocess technology stack used in cell processing.
• Terumo BCT: Global provider of blood and cell processing technologies and devices, including cell collection, processing, and expansion systems. Comparable as an enabling technology vendor in the cell processing workflow that Biomaster and its customers depend on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomaster